By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Orexigen Therapeutics, Inc. 

48 Wall Street
Suite 1100
New York  New York  10005  U.S.A.
Phone: 212-918-4650 Fax: 212-918-4801


SEARCH JOBS


Industry
Biotechnology






Company News
Orexigen Therapeutics, Inc. (OREX) Reports Financial Results For The Fourth Quarter And Year Ended December 31, 2014 2/25/2015 9:30:19 AM
Orexigen Therapeutics, Inc. (OREX) To Speak At The 2015 RBC Capital Markets Global Healthcare Conference 2/23/2015 7:58:36 AM
Orexigen Therapeutics, Inc. (OREX) To Host Full Year And Fourth Quarter 2014 Financial Results Conference Call And Webcast 2/23/2015 7:39:25 AM
Orexigen Therapeutics, Inc. (OREX) To Speak At The Leerink Global Healthcare Conference 2/9/2015 11:46:58 AM
Orexigen Therapeutics, Inc. (OREX) Provides Progress Update on Mysimba European Marketing Authorization 2/9/2015 9:41:19 AM
Orexigen Therapeutics, Inc. (OREX) To Present At The J.P. Morgan 2015 Healthcare Conference 1/8/2015 9:58:55 AM
Orexigen Therapeutics, Inc. (OREX)'s Mysimba (Naltrexone Hcl / Bupropion Hcl Prolonged Release) Receives Positive CHMP Opinion Recommending Approval For Weight Management In The European Union 12/19/2014 7:48:49 AM
Orexigen Therapeutics, Inc. (OREX) To Present At The Piper Jaffray Healthcare Conference 11/26/2014 10:18:37 AM
Orexigen Therapeutics, Inc. (OREX) Announces Allowance Of New U.S. Patent For Contrave (Naltrexone Hcl / Bupropion Hcl Extended Release) 11/21/2014 10:13:32 AM
Orexigen Therapeutics, Inc. (OREX) Reports Results For The Third Quarter Ended September 30, 2014 11/10/2014 8:46:48 AM
12345678910...
//-->